Bajaj Priyanka, Tripathy Rajan K, Aggarwal Geetika, Pande Abhay H
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali) 160062, Punjab, India.
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali) 160062, Punjab, India.
Protein Expr Purif. 2015 Nov;115:95-101. doi: 10.1016/j.pep.2015.05.011. Epub 2015 May 21.
Human PON1 (h-PON1) is a Ca(2+)-dependent serum enzyme and can hydrolyze (and inactivate) a wide range of substrates. It is a multifaceted enzyme and exhibit anti-inflammatory, anti-oxidative, anti-atherogenic, anti-diabetic, anti-microbial, and organophosphate (OP)-detoxifying properties. Thus, h-PON1 is a strong candidate for the development of therapeutic intervention against these conditions in humans. Insufficient hydrolyzing activity of native h-PON1 against desirable substrate affirms the urgent need to develop improved variant(s) of h-PON1 having enhanced activity. Production of recombinant h-PON1 (rh-PON1) using an Escherichia coli expression system is a key to develop such variant(s). However, generation of rh-PON1 using E. coli expression system has been elusive until now because of the aggregation of over-expressed rh-PON1 protein in inactive form as inclusion bodies (IBs) in the bacterial cells. In this study, we have over-expressed rh-PON1(wt) and rh-PON1(H115W;R192K) proteins as IBs in E. coli, and refolded the inactive enzymes present in the IBs to their active form using in vitro refolding. The active enzymes were isolated from the refolding mixture by ion-exchange chromatography. The catalytic properties of the refolded enzymes were similar to their soluble counterparts. Our results show that the pure and the active variant of rh-PON1 enzyme having enhanced hydrolyzing activity can be produced in large quantities using E. coli expression system. This method can be used for the industrial scale production of rh-PON1 enzymes and will aid in developing h-PON1 as a therapeutic candidate.
人对氧磷酶1(h-PON1)是一种依赖钙离子的血清酶,能够水解(并使其失活)多种底物。它是一种具有多方面功能的酶,具有抗炎、抗氧化、抗动脉粥样硬化、抗糖尿病、抗微生物以及有机磷解毒特性。因此,h-PON1是针对人类这些病症开发治疗性干预措施的有力候选对象。天然h-PON1对理想底物的水解活性不足,这表明迫切需要开发活性增强的h-PON1改良变体。利用大肠杆菌表达系统生产重组h-PON1(rh-PON1)是开发此类变体的关键。然而,迄今为止,利用大肠杆菌表达系统生成rh-PON1一直难以实现,因为过量表达的rh-PON1蛋白以无活性形式聚集在细菌细胞中形成包涵体(IBs)。在本研究中,我们在大肠杆菌中以包涵体形式过量表达了rh-PON1(野生型)和rh-PON1(H115W;R192K)蛋白,并通过体外复性将包涵体中存在的无活性酶复性为活性形式。通过离子交换色谱从复性混合物中分离出活性酶。复性酶的催化特性与其可溶性对应物相似。我们的结果表明,利用大肠杆菌表达系统可以大量生产具有增强水解活性的rh-PON1酶的纯活性变体。该方法可用于rh-PON1酶的工业规模生产,并将有助于将h-PON1开发为一种治疗候选物。